+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anticoagulant Reversal Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

  • PDF Icon


  • 115 Pages
  • April 2023
  • Region: Global
  • Mordor Intelligence
  • ID: 4896183
UP TO OFF until Sep 30th 2023

Quick Summary:

In the ever-evolving pharmaceutical industry, the market for anticoagulant reversal drugs is a beacon of growth. These critical medications play a significant role in managing multiple cardiovascular indications, atrial fibrillation, intracranial and gastrointestinal hemorrhages, and conditions increasingly common within the global ageing population. As these health issues show no sign of abating, the demand for anticoagulant reversal drugs is fundamental to healthcare systems around the world.

Also driving growth in this market is the rise in blood diseases, like anemia, which further increases the need for these drugs. Despite potential drug side-effects, the development and diversification of products are projected to augment the industry's status quo in the foreseeable future. Purchasing our comprehensive market research report on Anticoagulant Reversal Drugs will provide you with profound insights into the market trends, key industry players, and the future potential of this crucial sector.

The anticoagulant reversal drugs market is expected to witness a CAGR of 12.01% over the forecast period.

COVID-19 significantly impacted the anticoagulant reversal drugs market owing to the increasing pace of research activities on COVID-19 infection. For instance, per the data from the American Journal of Cardiovascular Drugs, in 2020, more than 10 clinical trials were in progress to evaluate the potential of factor Xa inhibitors in COVID-19 patients, and research on strategies for the parenteral administration of these drugs was worked upon to be used in critically ill COVID-19 patients. Additionally, it was observed that several patients with COVID-19 had developed abnormal blood clotting, which increased the use of anticoagulants during the pandemic. Therefore, the COVID-19 pandemic had a significant impact on the market studied. However, the market is currently reaching its pre-pandemic nature and is expected to witness healthy growth in the coming years.

The major factors driving the market are a rise in the global prevalence of multiple cardiovascular indications, atrial fibrillation, an increase in intracranial and gastrointestinal hemorrhages, and the increasing geriatric population. As per the 2021 data from the CDC, every year, 805,000 people in the United States have a heart attack, 605,000 of these result in a first-time heart attack, while 200,000 are caused by previous heart attacks. Similarly, as stated by the American Heart Association 2021 journal, it is estimated that by the year 2035, more than 130 million adults in the United States will have some type of heart disease. The increasing burden of cardiovascular diseases in major countries such as the United States is believed to propel market growth over the forecast period.

Additionally, the increasing burden of blood diseases is augmenting the demand for anticoagulant reversal drugs. For instance, as per the National Family Health Surveys (NFHS) conducted in 2021, the prevalence of anemia in Indian adults was around 59% in women and 31% in men in 2021. With this development, there will be market growth in the coming years.

However, the side effects associated with the drug may restrain the market during the forecast period.

Anticoagulant Reversal Drugs Market Trends

The Coagulation Factors Segment is Expected to Hold the Largest Market Share

Coagulation factors, also called clotting factors, are the proteins in the blood. They help form a blood clot to stop bleeding when an injury occurs.

It has been observed that COVID-19 caused blood clotting in most patients, propelling the demand for anticoagulants during the pandemic. According to a research article published in the Lancet in 2020, coagulopathy of varying severity was observed in most COVID-19-infected patients, characterized by increased D-dimer levels and fibrinogen or fibrin degradation products, along with abnormal measurements in the prothrombin time, acute partial thromboplastin time, and platelet counts. Hence, thorough research on various factors affecting bleeding and coagulation among COVID-19 patients was carried out to understand the pathophysiology of the causal organism.

Besides, Andexxa is the first and only approved drug for reversing the effect of coagulation factor Xa inhibitors in adult patients. Portola Pharmaceuticals introduced Andexxa in the year 2018, which contributed to a major share of the company's revenue. Currently, Andexxa is sold by AstraZeneca because it acquired Alexion Pharmaceuticals, the parent company of Portola Pharmaceuticals in July 2021.

Additionally, the increasing research activities in the development of new products by companies are expected to drive the growth of the studied segment over the forecast period. For instance, the American College of Cardiology stated in its June 2022 study that for atrial fibrillation, there will be a growing new drug development wave that will fulfill the need for anticoagulants in the coming years. With the focus of companies on developing anticoagulants, the segment is believed to witness strong growth over the forecast period.

North America Dominates the Market and is Expected to do the Same in the Forecast Period

North America is expected to dominate the overall anticoagulant reversal drugs market throughout the forecast period. The high growth of the studied market in North America is due to factors such as the availability of direct reimbursement policies and the region's advanced healthcare infrastructure.

COVID-19 significantly impacted the market studied in the North American region due to the emergence of the relationship between COVID-19 infection and blood disorders. For instance, as per 2020 data from the American Journal of Hematology, COVID-19-infected patients admitted with severe complications associated with the viral infection were found to exhibit high levels of blood-clotting protein Factor V, which could eventually lead to the development of blood clots in various organs.

Moreover, the United States holds the largest market share due to the accelerated drug approval initiative by the US FDA and the initiation of various prevention programs and awareness workshops for blood disorders by the CDC, which is expected to drive market growth in this region. Also, the high prevalence of cardiovascular diseases in the United States drives the studied market. According to the American Heart Association 2021 data, myocardial infarction is more common in the United States and it has been observed that every 40 seconds at least one person have a myocardial infarction. Additionally, coronary events occur in about 1,055,000 individuals annually, including 720,000 new and 335,000 recurrent coronary events.

Additionally, several key players in the studied market have a base in the United States and are expected to explore the market through R&D activities and product approvals. Thus, given the aforementioned factors, the anticoagulant reversal drugs market is anticipated to grow significantly over the forecast period in North America.

Anticoagulant Reversal Drugs Market Competitor Analysis

The anticoagulant reversal drugs market is consolidated and consists of a few major players. The key players in the studied market include Pfizer Inc., Boehringer Ingelheim GmbH, CSL Behring Limited, Portola Pharmaceuticals Inc., and Octapharma AG, among others. Some prominent players are vigorously making acquisitions with other companies to consolidate their market positions across the globe, while others are launching generic products and increasing investments in research and development activities.

Additional benefits of purchasing the report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Geriatric Population and Growing Blood Disorders
4.2.2 New Product Launches due to Accelerated Drug Approval Initiative by USFDA
4.3 Market Restraints
4.3.1 Side Effects Associated with the Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size - Value in USD million)
5.1 By Drug Class
5.1.1 Prothrombin Complex Concentrates
5.1.2 Coagulation Factors
5.1.3 Monoclonal Antibodies
5.1.4 Phytonadione
5.1.5 Other Drug Classes
5.2 By End User
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Other End Users
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Portola Pharmaceuticals Inc.
6.1.2 Boehringer Ingelheim GmbH
6.1.3 CSL Behring Limited
6.1.4 Pfizer Inc.
6.1.5 Octapharma AG
6.1.6 Bausch Health Companies Inc.
6.1.7 Amneal Pharmaceuticals Inc.
6.1.8 Fresenius Kabi AG
6.1.9 Perosphere Pharmaceuticals Inc.
6.1.10 Ferring Pharmaceuticals Inc.
6.1.11 Midas Pharma GmbH
6.1.12 Healthy Life Pharma Pvt. Ltd
6.1.13 Pharma Cure Laboratories
6.1.14 Nischi Lifesciences

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Portola Pharmaceuticals Inc.
  • Boehringer Ingelheim GmbH
  • CSL Behring Limited
  • Pfizer Inc.
  • Octapharma AG
  • Bausch Health Companies Inc.
  • Amneal Pharmaceuticals Inc.
  • Fresenius Kabi AG
  • Perosphere Pharmaceuticals Inc.
  • Ferring Pharmaceuticals Inc.
  • Midas Pharma GmbH
  • Healthy Life Pharma Pvt. Ltd
  • Pharma Cure Laboratories
  • Nischi Lifesciences